Clinical trials: CD123+ Acute Myeloid Leukemia
Acute Leukemia, Acute Leukemia in Relapse
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of anti-CD123 CAR-T cells in treating patients diagnosed with refractory/relapsed acute leukemia in a dose-escalation way.
- Conditions
- Acute Leukemia, Acute Leukemia in Relapse, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemia
- Trial name
- NCT03672851
- Testing
- anti-CD123 CAR-T treatment
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Leukemia, Leukemia, Myeloid
Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia
This is a single arm study to evaluate the efficacy and safety of CD123-targeted CAR-T cells therapy for patients with relapsed/refractory Acute Myeloid Leukemia.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Trial name
- NCT04272125
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric
CD123 Redirected T Cells for AML in Pediatric Subjects
Phase 1 open-label study to evaluate the safety of intravenously administered, lentivirally transduced T cells expressing anti-CD123 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ /4-1BB) costimulatory domains…
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Pediatric, Acute Myeloid Leukemia, Refractory
- Trial name
- NCT04678336
- Testing
- CART123 cells; cyclophosphamide; fludarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Pennsylvania
Relapsed/Refractory AML
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)
The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive.
- Trial name
- NCT03631576
- Testing
- CD123/CLL1 CAR-T Cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fujian Medical University
Acute Myeloid Leukemia
Multiple CAR-T Cell Therapy Targeting AML
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple CAR T-cell therapy which combines CAR T cells against CLL-1 with CAR T cells targeting CD123 or CD33 in patients with relapsed and…
- Trial name
- NCT04010877
- Testing
- CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Acute Myeloid Leukemia
Universal CAR-T Cells Targeting AML
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T-cell products targeting CLL-1, CD33, CD38 and CD123 in patients with relapsed and refractory AML.
- Trial name
- NCT05995041
- Testing
- CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Hematologic Malignancy, Acute Myeloid Leukemia
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD123-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
- Trial name
- NCT04156256
- Testing
- CD123-CD33 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
AML/MDS, B-ALL
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN).
- Conditions
- AML/MDS, B-ALL, T-ALL, BPDCN
- Trial name
- NCT04318678
- Testing
- CD123-CAR T, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- St. Jude Children's Research Hospital
AML, Acute Myeloid Leukemia
Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD33 or CD123 or both sequentially in the treatment of Acute Myelocytic Leukemia.
- Conditions
- AML, Acute Myeloid Leukemia, AML, Adult Recurrent, AML, Adult
- Trial name
- BAH244 (NCT06420063)
- Testing
- CD123/CD33 CART
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Acute Biphenotypic Leukemia, Acute Leukemia
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
This phase II trial studies how well flotetuzumab works in treating patients with CD123 positive blood cancer that has come back or does not respond to treatment.
- Conditions
- Acute Biphenotypic Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hairy Cell Leukemia
- Trial name
- NCT03739606
- Testing
- Anti-CD123/CD3 Monoclonal Antibody MGD006
- Sponsor
- City of Hope Medical Center
Relapsed/Refractory Acute Myeloid Leukemia(AML)
CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a group of genetically highly heterogeneous malignant disease . The disease is the most common type of adult acute leukemia. Overall survival (OS) was less than 50% in 5 years.
- Trial name
- AML (NCT03473457)
- Testing
- CART therapy in Acute myeloid leukemia(AML)
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Zhujiang Hospital
AML (Acute Myeloid Leukemia), BPDCN
CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults
The purpose of this phase I/II clinical trial is to test CARCIK-CD123/33 cells to treat patients with R/R AML/BPDCN, who have otherwise exhausted conventional treatment options.
- Trial name
- Dual CARCIK (NCT07877610)
- Testing
- CARCIK CD123/33 infusion
- Where
- 2 sites in Italy
- Volunteers
- 18 people
- Sponsor
- Fondazione Matilde Tettamanti Menotti De Marchi Onlus
Acute Myelocytic Leukemia
Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia
This is an open, single-arm, phase I clinical study to evaluate efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting CD123 in the treatment of Acute Myelocytic Leukemia.
- Trial name
- NCT03796390
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
This phase I trial studies the side effects and the best dose of genetically modified T-cells after lymphodepleting chemotherapy in treating patients with acute myeloid leukemia or blastic plasmacytoid dendritic cell neoplasm…
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia, Late Relapse of Acute Myeloid Leukemia
- Trial name
- NCT02159495
- Testing
- cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- City of Hope Medical Center
Leukemia, Leukemia, Myeloid
CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia
There are limited options for treatment of relapse/refractory acute myeloid leukemia (AML). CD123 CAR-T cells may have an attractive and permanent effect on anti-tumor.
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
- Trial name
- NCT04265963
- Testing
- CD123 CAR-T cells
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Acute Myeloid Leukemia
Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multi-CAR T cell therapy targeting different AML surface antigens in patients with relapsed or refractory acute myeloid leukemia (AML).
- Trial name
- NCT03222674
- Testing
- Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Leukemia, Myeloid, Acute
CART-123 FOR Relapsed/Refractory Acute Myelocytic Leukemia（AML）
The purpose of this study is to evaluate the safety and efficiency of CD123-Targeted CAR-T in Treating Patients with relapsed/refractory AML
- Trial name
- NCT03556982
- Testing
- CART-123 cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Acute Myeloid Leukemia (AML)
CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
This study is designed to evaluate the safety and effectiveness of CART123 cells either alone or when combined with ruxolitinib in pediatric and young adult subjects with relapsed or refractory AML.
- Trial name
- CART123 (NCT07464951)
- Testing
- Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stephan Grupp MD PhD
Acute Myeloid Leukemia
IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia
A Study of IL3 CAR-T Cell Therapy for Patients With CD123 Positive Relapsed and/or Refractory Acute Myeloid Leukemia.
- Trial name
- NCT04599543
- Testing
- IL3 CAR T-cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Acute Myeloid Leukemia
Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML
This is an open-label Phase Ia/Ib clinical study of tagraxofusp-erzs, a novel cytokine-drug conjugate that links interleukin-3 with a truncated diphtheria toxin, in combination with gemtuzumab ozogamicin for patients with…
- Trial name
- GO-TAG (NCT05716009)
- Testing
- Dose Escalation -tagraxofusp-erzs, Dose Expansion at RP2D -tagraxofusp-erzs
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins